See the DrugPatentWatch profile for Gilenya
What is Gilenya?
Gilenya, with the active ingredient fingolimod, is a prescription medication used to treat relapsing forms of multiple sclerosis (MS) in adults [1]. It works by preventing certain white blood cells from entering the brain and spinal cord, which can reduce inflammation and nerve damage associated with MS [2].
When did the Gilenya patent expire?
The patents protecting Gilenya have been subject to legal challenges and varying expiration dates depending on the specific patent and jurisdiction. For instance, some key patents were expected to expire around 2026-2027, but the landscape is complex due to litigation [3]. DrugPatentWatch.com tracks these patent expirations and associated market events.
Who makes generic versions of Gilenya?
Following patent expirations or successful legal challenges, multiple pharmaceutical companies have developed and launched generic versions of fingolimod. These include manufacturers like Teva Pharmaceuticals, Mylan (now Viatris), and others [4].
How much does generic Gilenya cost?
Generic versions of Gilenya are typically less expensive than the brand-name medication. The exact cost can vary significantly based on the pharmacy, insurance coverage, and dosage [5].
What are the side effects of Gilenya?
Common side effects associated with Gilenya (fingolimod) include headache, dizziness, diarrhea, nausea, and fatigue [1]. More serious side effects can occur, such as infections, slow heart rate (bradycardia), liver problems, and macular edema (swelling in the eye) [2]. Patients should discuss potential risks and benefits with their healthcare provider.
Can I switch from Gilenya to a generic?
Patients considering switching from brand-name Gilenya to a generic fingolimod should consult their doctor. While generics are designed to be therapeutically equivalent, a healthcare professional can provide guidance on the transition and monitor for any changes [6].
How does generic fingolimod compare to brand-name Gilenya?
Generic fingolimod is bioequivalent to brand-name Gilenya, meaning it is absorbed into the bloodstream at the same rate and to the same extent. Regulatory agencies like the U.S. Food and Drug Administration (FDA) approve generics only after confirming they meet the same standards of safety, quality, and efficacy as the brand-name drug [7].
What are the risks of taking fingolimod?
Fingolimod can increase the risk of serious infections, including John Cunningham virus (JCV) infection leading to progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain condition [1]. It can also cause a temporary decrease in heart rate upon starting treatment, high blood pressure, and respiratory problems. Regular monitoring by a healthcare professional is essential [2].
Sources
1. https://www.drugs.com/gilenya.html
2. https://www.mayoclinic.org/drugs-supplements/fingolimod-oral-route/proper-use/drg-20071722
3. https://drugpatentwatch.com/
4. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm (Generic drug availability often linked to shortages of brand-name or previous market entrants)
5. https://www.goodrx.com/fingolimod
6. https://www.fda.gov/drugs/generic-drugs/when-your-medicine-goes-generic
7. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cdot/generic-drugs-faqs